Testing effectiveness (Phase 2)Study completedNCT02249221
What this trial is testing
Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
Who this might be right for
Influenza
Green Cross Corporation 84